SCHEMBL4766565

SCHEMBL4766565

CS(=O)(=O)Nc1ccc(-c2ccc(S(=O)(=O)C(F)(F)F)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 8/20 1.00
CA2 P00918 2/20 0.53
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA9 Q16790 1/20 0.53
ALDH1A1 P00352 4/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
MAPT P10636 1/20 0.51
CYP2C9 P11712 1/20 0.47
LMNA P02545 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
HSD17B1 P14061 1/20 0.46
HSD17B2 P37059 1/20 0.46
KEAP1 Q14145 1/20 0.46
GAA P10253 1/20 0.45
MAPK1 P28482 1/20 0.45
PTGS2 P35354 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536768 0.83 KIF11 (0.71) KIF11CA2CA12CA1CA9
SCHEMBL31041151 0.81 KIF11 (0.79) KIF11CA2CA12CA1CA9
Lithium SCHEMBL31041154 0.79 KIF11 (0.76) KIF11CA2CA12CA1CA9
SCHEMBL3380022 0.79 KIF11 (1.00) KIF11CA2CA1GAA
SCHEMBL15771505 0.77 KIF11 (0.62) KIF11CA2CA12CA1CA9
SCHEMBL5431851 0.76 KIF11 (0.61) KIF11CA2CA1ALDH1A1SMN1; SMN2
SCHEMBL4659812 0.76 KIF11 (0.66) KIF11CA2CA12CA1CA9
SCHEMBL13348599 0.76 KIF11 (0.61) KIF11CA2CA12CA1CA9
SCHEMBL3378495 0.75 KIF11 (1.00) KIF11ALDH1A1SMN1; SMN2LMNAGAA
SCHEMBL4659819 0.75 KIF11 (0.63) KIF11CA2CA12CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1694281-A4 BIPHENYL COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2008-12-24 EP claimed
US-20070259951-A1 Compounds, Compositions and Methods SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 US claimed
EP-1694281-A2 BIPHENYL COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2006-08-30 EP claimed
WO-2005060692-A2 BIPHENYL COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2005-07-07 WO claimed
US-20070259951-A1 Compounds, Compositions and Methods SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259951-A1 Compounds, Compositions and Methods ALPP, PCNA, MKI67 KIF11 824/4885CA2 2768/4885CA12 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.